JAYSON GESULGA: Open Payments
NPI 1972989721 · URBANDALE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$299,643 in 574 payments from 14 companies in 2025. Trend: 2023 $166,749 · 2024 $258,559 · 2025 $299,643
Speaker / faculty: $222,015Travel & lodging: $56,394Consulting: $11,868Food & beverage: $9,225Education: $141
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 172 | $102,111 |
| Neurocrine BioSciences, Inc. | 170 | $86,248 |
| Teva Pharmaceuticals USA, Inc. | 89 | $58,965 |
| Alkermes, Inc. | 47 | $21,186 |
| E.R. Squibb & Sons, L.L.C. | 36 | $17,007 |
| ABBVIE INC. | 29 | $10,855 |
| Otsuka America Pharmaceutical, Inc. | 17 | $2,780 |
| Axsome Therapeutics, Inc. | 4 | $289 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $56 |
| Lundbeck LLC | 2 | $42 |
Products named: CAPLYTA, INGREZZA, AUSTEDO XR, LYBALVI, COBENFY, VRAYLAR, UZEDY, ABILIFY MAINTENA.
Industry payments across IA — which companies pay providers there.
